Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 25;50(7):1441-1443.
doi: 10.1093/ced/llaf105.

Circulating IgE levels as a biomarker for treatment response to dupilumab among patients with prurigo nodularis

Anjali J D'Amiano  1   2 , Yagiz Matthew Akiska  1   2 , Jack Kollings  1   2 , Aaron Bao  1   2 , Vrinda Madan  1   2 , Emily Ma  1   2 , Shivani S Patel  1   2 , Shawn G Kwatra  1   2
Affiliations

Circulating IgE levels as a biomarker for treatment response to dupilumab among patients with prurigo nodularis

Anjali J D'Amiano et al. Clin Exp Dermatol. .

Abstract

In this retrospective study, we investigated the role of baseline IgE levels in predicting the treatment response to dupilumab in patients with prurigo nodularis (PN). Our findings showed that patients with elevated IgE experienced significantly greater relief from pruritus following dupilumab treatment, suggesting that IgE could serve as a biomarker for identifying individuals who are more likely to benefit from treatments that target interleukin (IL)-4 and IL-13. These results support the development of personalized treatment strategies based on inflammatory profiles in patients with PN.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: S.G.K. is an advisory board member/consultant for AbbVie, Aslan Pharmaceuticals, Arcutis Biotherapeutics, Castle Biosciences, Celldex Therapeutics, Galderma, Genzada Pharmaceuticals, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer and Sanofi. All other authors report no conflicts of interest.

References

    1. Liao V, Cornman HL, Ma E, Kwatra SG. Prurigo nodularis: new insights into pathogenesis and novel therapeutics. Br J Dermatol 2024; 190:798–810. - PMC - PubMed
    1. Huang AH, Canner JK, Kang S, Kwatra SG. Analysis of real-world treatment patterns in patients with prurigo nodularis. J Am Acad Dermatol 2020; 82:34–6. - PubMed
    1. Yosipovitch G, Mollanazar N, Ständer S et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med 2023; 29:1180–90. - PMC - PubMed
    1. Cornman HL, Manjunath J, Reddy SV et al. Comprehensive plasma cytokine and chemokine profiling in prurigo nodularis reveals endotypes in Type 2 inflammation. Sci Rep 2024; 14:8098. - PMC - PubMed
    1. Parthasarathy V, Cravero K, Xu L et al. The blood proteomic signature of prurigo nodularis reveals distinct inflammatory and neuropathic endotypes: a cluster analysis. J Am Acad Dermatol 2023; 88:1101–9. - PMC - PubMed

LinkOut - more resources